Observing patients with hypertrophic cardiomyopathy in France
French Hypertrophic Cardiomyopathy Observatory
This study is tracking patients with hypertrophic cardiomyopathy in France to see how their health changes over time and to improve treatment for the condition.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 600 (estimated) |
| Ages | 15 Years and up |
| Sex | All |
| Sponsor | French Cardiology Society Academic / other |
| Locations | 1 site (Paris) |
| Trial ID | NCT01091480 on ClinicalTrials.gov |
What this trial studies
This observational study aims to monitor patients diagnosed with hypertrophic cardiomyopathy (HCM) across 50 hospitals in France. It will collect both retrospective and prospective data, including demographics, clinical assessments, and treatment histories. The study will follow patients for up to five years to gather comprehensive information on their health status and treatment outcomes. The goal is to better understand the disease profile and improve diagnostic and therapeutic approaches for HCM in the French population.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals aged 15 years and older who have been diagnosed with hypertrophic cardiomyopathy.
Not a fit: Patients with significant aortic stenosis or those who refuse to participate in the study may not benefit from this research.
Why it matters
Potential benefit: If successful, this study could lead to improved diagnosis and treatment strategies for patients with hypertrophic cardiomyopathy.
How similar studies have performed: While there may be similar observational studies, this specific approach to monitoring HCM patients in France is novel and aims to fill a significant data gap.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥ 15 years old * Patient with HCM defined by an ultrasound thickness of the left ventricle ≥ 13 mm if familial or ≥ 15 mm if sporadic Exclusion Criteria: * Expressed refusal to participate in the study * Significant aortic stenosis (\<1 cm ²)
Where this trial is running
Paris
- European Georges Pompidou Hospital — Paris, France (Recruiting)
Study contacts
- Study coordinator: Albert Hagege
- Email: albert.hagege@egp.ap-hop-paris.fr
- Phone: 33(0)156092897
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.